No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
IART240816C35000
- 0.25
- -0.43-63.24%
15min DelayClose Jul 22 12:49 ET
0.68High0.25Low
0.68Open0.68Pre Close9 Volume0 Open Interest35.00Strike Price268.00Turnover71.72%IV11.80%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type0.3306Delta0.0608Gamma26.83Leverage Ratio-0.0442Theta0.0064Rho8.87Eff Leverage0.0301Vega
Intraday
- 5D
- Daily
News
Earnings Preview: Integra LifeSciences (IART) Q2 Earnings Expected to Decline
Bullish Integra LifeSciences Holdings Insiders Loaded Up On US$2.50m Of Stock
Integra LifeSciences Is Maintained at Hold by Truist Securities
Integra LifeSciences Is Maintained at Hold by Truist
Integra LifeSciences Price Target Raised to $32.00/Share From $25.00 by Truist Securities
Integra LifeSciences Price Target Raised to $32.00/Share From $25.00 by Truist
A Quick Look at Today's Ratings for Integra Lifesciences(IART.US), With a Forecast Between $26 to $48
On Jul 16, major Wall Street analysts update their ratings for $Integra Lifesciences(IART.US)$, with price targets ranging from $26 to $48.Morgan Stanley analyst Drew Ranieri maintains with a sell
Integra Lifesciences: Strategic Manufacturing Shifts Amid Supply Constraints – A Hold Rating Perspective
Comments
$Integra Lifesciences(IART.US$ Integra LifeSciences Price Target Cut to $25.00/Share From $45.00 by Wells Fargo
EPS growth doesn't align with share price, indicating it may not reflect business performance or growth expectations may have been high. Integra LifeSciences Holdings' performance led to a 3% annual loss for shareholders over five years. Investors should note 3 warning signs.
1
1
Insider transactions suggest a positive outlook for Integra LifeSciences Holdings, with insiders net buying the stock. The level of insider ownership indicates a reasonable degree of alignment with shareholder interests.
1
Integra LifeSciences Holdings trades at a low price, suggesting a buying opportunity. Higher cash flow is expected, potentially boosting share valuation. The positive outlook seems not fully factored into the share price, indicating it's not too late to buy IART.
Read more
Money MoverOP : $Medtronic (MDT.US)$ $Intuitive Surgical (ISRG.US)$